SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01570699

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

COMT Val158Met Polymorphism in Opiate-using Subjects Without Lifetime Opiate Dependence

The main objective is to compare the genotypes of the COMT Val158Met polymorphism between opiate-users and opiate-dependent subjects. The secondary objective is to constitute a sample of opiate-users without any lifetime opiate dependence.

NCT01570699 Opioid-related Disorders Opiate Dependence Opiate Addiction Opiate Abuse
MeSH: Opioid-Related Disorders

1 Interventions

Name: COMT polymorphism

Description: The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity

Type: Genetic

2: patients included in METHADOSE study 1: opiate-non dependent patients


Primary Outcomes

Measure: Number of subjects with each COMT genotype (Val/Val, Val/Met and Met/Met) in the opiate-users' group and in the opiate-dependent subjects' group

Time: Day 0

Secondary Outcomes

Measure: Score on the M.I.N.I. (Mini-International Neuropsychiatric Interview) on the day of the inclusion

Time: Day 0

Measure: Score on the BIS (Barratt Impulsivity Scale) on the day of the inclusion

Time: Day 0

Measure: Score on the TCI (Cloninger's Temperament and Character Inventory) on the day of the inclusion

Time: Day 0

Measure: Score on the WURS (Wender Utah Rating Scale) on the day of the inclusion

Time: Day 0

Measure: Score on the ASRS(Self-Report Scale) on the day of the inclusion

Time: Day 0

Measure: Score on the MOPS (Measure Of Parental Style) on the day of the inclusion

Time: Day 0

Measure: Score on the Questionnaire of family breakdowns on the day of the inclusion

Time: Day 0

Measure: Score on the CD-RISC (Connor-Davidson Resilience scale) on the day of the inclusion

Time: Day 0

Measure: Score on the CTQ (Childhood trauma questionnaire) on the day of the inclusion

Time: Day 0

Time Perspective: Cross-Sectional

Case Control


There is one SNP

SNPs


1 V158M

COMT Val158Met Polymorphism in Opiate-using Subjects Without Lifetime Opiate Dependence. --- Val158Met ---

Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients The main objective is to compare the genotypes of the COMT Val158Met polymorphism between opiate-users and opiate-dependent subjects. --- Val158Met ---

Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients The main objective is to compare the genotypes of the COMT Val158Met polymorphism between opiate-users and opiate-dependent subjects. --- Val158Met --- --- Val158Met ---

Inclusion Criteria: - Patient over 18 years old - Caucasian patients - Clinical diagnosis of lifetime opiate-using disorder (consumption over 10 times of illicit opiates (heroin, buprenorphine, methadone or morphine)) - Not lifetime history of opioid dependence (DSMIV) - Patients with health insurance coverage - Patient was treated with opioids analgesics to alleviate 2 or 3 in their lives Exclusion Criteria: - Non-Caucasian patients - Patients who cannot give their consent and/or who refuse the collection of genetic data - Patients with no health insurance coverage Inclusion Criteria: - Patient over 18 years old - Caucasian patients - Clinical diagnosis of lifetime opiate-using disorder (consumption over 10 times of illicit opiates (heroin, buprenorphine, methadone or morphine)) - Not lifetime history of opioid dependence (DSMIV) - Patients with health insurance coverage - Patient was treated with opioids analgesics to alleviate 2 or 3 in their lives Exclusion Criteria: - Non-Caucasian patients - Patients who cannot give their consent and/or who refuse the collection of genetic data - Patients with no health insurance coverage Opioid-related Disorders Opiate Dependence Opiate Addiction Opiate Abuse Opioid-Related Disorders The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders, including addictions, as well as in impulsivity. --- Val158Met ---



HPO Nodes